Rays Power Infra announced closure of INR 127 Crore Equity Capital Fund Raise - Ardee Industries Limited Announced its Initial Public Offering (IPO) to open on Wednesday, August 05, 2026Price Band fixed at ₹ 50 per equity share of face value ₹2 each to ₹53 per equity share of the face value of ₹2 each - MS Dhoni Joins Malabar Gold & Diamonds as Brand Ambassador, Strengthening the Responsible Jeweller Promise - Croma opens new store at Sky-City Mall, Borivali, Croma now has 54 stores across the Mumbai Metropolitan Region (MMR) - Godrej Enterprises Group Strengthens Advanced Tooling Capabilities to Support India's Evolving Automotive Manufacturing Landscape - GOVINDA: A Tale of Faith, A thematic dance production comes to Mumbai - Juniper Green Energy Limited announced its ₹1800 crore Initial Public Offering (IPO) to open on July 30, 2026 Price Band fixed at ₹ 214 to ₹ 225 per equity share of face value of ₹ 10 each - Juniper Green Energy Limited announced its ₹1800 crore Initial Public Offering (IPO) to open on July 30, 2026 the Price Band fixed at ₹ 214 to ₹ 225 per equity share of face value of ₹ 10 each - Mahindra Holidays & Resorts India Ltd.- Q1FY27 Financial Results - Kokilaben Dhirubhai Ambani Hospital, Navi Mumbai Marks Eight Years with Release of Navi Mumbai Annual Health Report - Godrej Bloq Launches in Maharashtra; Supports Pink E-Rickshaw Distribution Initiative for Women Drivers in the state Godrej Bloq marks the newest entry as a personal care fragrance product by Godrej Consumer Products (GCPL)

Kotak Mahindra Capital Company Associates with Ignite Life Science Foundation for Research in Antimicrobial Resistance

Mumbai, 26th June 2023 (GNI): Under its corporate social responsibility (CSR) initiative, Kotak Mahindra Capital Company Ltd (“KMCC” / “Kotak Investment Banking”) today announced its association with Ignite Life Science Foundation (ILSF) for supporting research in the area of Antimicrobial Resistance (AMR).

The Bengaluru-based not-for-profit foundation, ILSF aims to leverage scientific discoveries for social good. The COVID-19 pandemic unmasked the growing problem of AMR in India, which can’t be solved through expensive antimicrobial drugs that are being developed. The country needs cheaper and more effective solutions that can minimise antimicrobial drug usage in all environments, including in agriculture. Solutions for AMR can come from new knowledge about resistance mechanisms in microorganisms and diagnostic methods to rapidly identify the organism causing an infection.

Ramesh Srinivasan, MD & CEO, Kotak Mahindra Capital Company said, “Our CSR Project on Healthcare includes preventive healthcare and sanitation. We are pleased to associate with Ignite Life Science Foundation to provide CSR funding for research in the area of Antimicrobial Resistance. We believe that our CSR project is likely to produce outcomes that are of immense benefit, given the scale and importance of these problems for human health.”

Dr. T. S. Balganesh, President of GangaGen Biotechnologies Pvt Ltd and a member of the Scientific Advisory Board of Ignite Life Science Foundation said, “Antimicrobial Resistance is on the verge of upsetting all the gains that we have made with modern medicine. Novel therapeutics aimed to address this global and local problem is urgently needed as a part of the ‘one health’ concept for sustaining our race. AMR is a priority area under India’s G-20 presidency. Increasing our collective effort through funding for research, awareness and stewardship will surely make an impact towards combating this potential ‘pandemic’.”

KMCC’s CSR Project will act as a triaging and a support mechanism to ensure that good ideas in the field of AMR thrive to a stage where they can be worked on by industry partners or collaborators.

Kotak Karma is the Corporate Social Responsibility (CSR) identity of Kotak Mahindra Group.ends GNI

Be the first to comment on "Kotak Mahindra Capital Company Associates with Ignite Life Science Foundation for Research in Antimicrobial Resistance"

Leave a comment

Your email address will not be published.


*